Laboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, University of California Irvine, School of Medicine, Irvine, CA, United States.
Department of Pathology and Laboratory Medicine, School of Medicine, University of California Irvine, Irvine, CA, United States.
Front Immunol. 2024 Mar 28;15:1343716. doi: 10.3389/fimmu.2024.1343716. eCollection 2024.
Cross-reactive SARS-CoV-2-specific memory CD4 and CD8 T cells are present in up to 50% of unexposed, pre-pandemic, healthy individuals (UPPHIs). However, the characteristics of cross-reactive memory CD4 and CD8 T cells associated with subsequent protection of asymptomatic coronavirus disease 2019 (COVID-19) patients (i.e., unvaccinated individuals who never develop any COVID-19 symptoms despite being infected with SARS-CoV-2) remains to be fully elucidated.
This study compares the antigen specificity, frequency, phenotype, and function of cross-reactive memory CD4 and CD8 T cells between common cold coronaviruses (CCCs) and SARS-CoV-2. T-cell responses against genome-wide conserved epitopes were studied early in the disease course in a cohort of 147 unvaccinated COVID-19 patients who were divided into six groups based on the severity of their symptoms.
Compared to severely ill COVID-19 patients and patients with fatal COVID-19 outcomes, the asymptomatic COVID-19 patients displayed significantly: (i) higher rates of co-infection with the 229E alpha species of CCCs (α-CCC-229E); (ii) higher frequencies of cross-reactive functional CD134CD137CD4 and CD134CD137CD8 T cells that cross-recognized conserved epitopes from α-CCCs and SARS-CoV-2 structural, non-structural, and accessory proteins; and (iii) lower frequencies of CCCs/SARS-CoV-2 cross-reactive exhausted PD-1TIM3TIGITCTLA4CD4 and PD-1TIM3TIGITCTLA4CD8 T cells, detected both and .
These findings (i) support a crucial role of functional, poly-antigenic α-CCCs/SARS-CoV-2 cross-reactive memory CD4 and CD8 T cells, induced following previous CCCs seasonal exposures, in protection against subsequent severe COVID-19 disease and (ii) provide critical insights into developing broadly protective, multi-antigen, CD4, and CD8 T-cell-based, universal pan-Coronavirus vaccines capable of conferring cross-species protection.
多达 50%的未暴露、大流行前的健康个体(UPPHIs)中存在交叉反应性 SARS-CoV-2 特异性记忆 CD4 和 CD8 T 细胞。然而,与无症状 2019 年冠状病毒病(COVID-19)患者(即从未出现任何 COVID-19 症状但仍感染 SARS-CoV-2 的未接种疫苗个体)随后保护相关的交叉反应性记忆 CD4 和 CD8 T 细胞的特征仍有待充分阐明。
本研究比较了普通感冒冠状病毒(CCCs)和 SARS-CoV-2 之间交叉反应性记忆 CD4 和 CD8 T 细胞的抗原特异性、频率、表型和功能。在一个由 147 名未接种疫苗的 COVID-19 患者组成的队列中,在疾病早期研究了针对全基因组保守表位的 T 细胞反应,这些患者根据症状的严重程度分为六组。
与严重 COVID-19 患者和 COVID-19 死亡患者相比,无症状 COVID-19 患者表现出明显的特征:(i)与 229E α 种 CCCs(α-CCC-229E)共感染的比率更高;(ii)更高频率的交叉反应性功能性 CD134CD137CD4 和 CD134CD137CD8 T 细胞,可交叉识别 α-CCCs 和 SARS-CoV-2 结构、非结构和辅助蛋白的保守表位;和(iii)更低频率的 CCCs/SARS-CoV-2 交叉反应性耗尽 PD-1TIM3TIGITCTLA4CD4 和 PD-1TIM3TIGITCTLA4CD8 T 细胞,无论是在 还是 均有检测到。
这些发现(i)支持了先前 CCCs 季节性暴露后诱导的功能性、多抗原性 α-CCCs/SARS-CoV-2 交叉反应性记忆 CD4 和 CD8 T 细胞在预防随后发生的严重 COVID-19 疾病中的关键作用,(ii)为开发广泛保护性、多抗原、CD4 和 CD8 T 细胞为基础的通用泛冠状病毒疫苗提供了重要见解,这些疫苗能够提供跨物种保护。